HDAC2 Regulates Site-Specific Acetylation of MDM2 and Its Ubiquitination Signaling in Tumor Suppression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Histone deacetylases (HDACs) are key epigenetic regulators and potential cancer therapeutic targets.
• The specific roles of individual HDACs, like HDAC2, in cancer pathways are not fully elucidated.
• Understanding HDAC functions is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To investigate the role of HDAC2 in regulating MDM2 acetylation and its downstream effects.
• To explore the therapeutic potential of targeting the HDAC2-MDM2-MULE pathway in cancer.
• To elucidate the mechanism by which HDAC inhibition suppresses synovial sarcomagenesis.

Main Methods:

• Western blotting to detect protein levels and acetylation.
• Immunoprecipitation assays to study protein interactions.
• Cell-based assays to assess MULE activity and SS18-SSX degradation.
• In vivo studies using mouse models of synovial sarcoma.

Main Results:

• HDAC2 inactivation leads to MDM2 acetylation at novel sites.
• This acetylation prevents MULE recognition and degradation by MDM2.
• HDAC inhibitor treatment increases MULE levels.
• Increased MULE targets the SS18-SSX fusion protein for degradation, inhibiting synovial sarcoma.

Conclusions:

• A novel HDAC2-dependent pathway linking acetylation signaling to the ubiquitin-proteasome system in cancer was identified.
• HDAC2 regulates MULE stability through MDM2 acetylation.
• Targeting this pathway with HDAC inhibitors shows therapeutic promise for synovial sarcoma by degrading SS18-SSX.